11 hours ago
1
Sundry Photography/iStock Editorial via Getty Images
- Prothena (NASDAQ:PRTA) will evaluate business options as well as drastically cut its workforce and spending as a result of the phase 3 trial failure of birtamimab in AL amyloidosis, a rare blood disorder.
- The candidate did not meet the primary
English (US) ·